Richmond News Now

Intermittent Claudication Market is Expected to Showcase Moderate Growth During the Forecast Period (2022-32), Predicts DelveInsight | Key Companies – Pluristem, Venturis Therapeutics, and Others

 Breaking News
  • No posts were found

Intermittent Claudication Market is Expected to Showcase Moderate Growth During the Forecast Period (2022-32), Predicts DelveInsight | Key Companies – Pluristem, Venturis Therapeutics, and Others

November 15
19:54 2022
Intermittent Claudication Market is Expected to Showcase Moderate Growth During the Forecast Period (2022-32), Predicts DelveInsight | Key Companies - Pluristem, Venturis Therapeutics, and Others
Delveinsight Business Research LLP
DelveInsight’s “Intermittent Claudication Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Intermittent Claudication market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Intermittent Claudication market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Intermittent Claudication Market

Intermittent Claudication: An Overview

Peripheral arterial disease (PAD) is a manifestation of atherosclerosis resulting in intermittent claudication (IC) or leg pain during physical activity. Intermittent claudication, the most common manifestation of PAD, is defined as activity-induced dysfunction and muscle pain (claudication pain) relieved by rest. 

According to the American College of Cardiology (2020), PAD affects 8.5 million individuals in the US and becomes prevalent with age (greater than 20% of cases are in patients over 80 years).

Intermittent Claudication Market Key Facts

  • The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) stated that the global prevalence of PAD was 120 million, representing 25.6% of the global burden of Cardiovascular disease and 1.7% of the overall global burden of disease.

  • According to Ohio State University Wexner Medical Center (n.d.), As much as 10% of the U.S. population has occasional claudication associated with peripheral vascular disease.

  • The pipeline of Intermittent Claudication is poor, with very few emerging drugs with good progression in clinical development. PLX-PAD, FGF-1, and others are evaluated in patients with Intermittent Claudication. These emerging therapies are in the early and mid-phase of the investigation. 

  • Globally, key players such as Pluristem Therapeutics, Pluristem, and others are in the process of developing potential therapies for the treatment of Intermittent Claudication.

  • As per DelveInsight, the Intermittent Claudication market is expected to grow by 2032 owing to the increase in the prevalent population of Intermittent Claudication, the high demand for therapies, and the approval of emerging therapies with a novel mechanism of action.

Intermittent Claudication Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Intermittent Claudication market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Intermittent Claudication market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Intermittent Claudication Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Intermittent Claudication Epidemiology Segmented by- – 

  • Total Prevalence of Peripheral artery disease

  • Diagnosed and Treatable Cases of Intermittent Claudication

  • Prevalent population of Intermittent claudication 

  • Gender-specific Prevalent Cases of Intermittent Claudication

Intermittent Claudication Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intermittent Claudication market or expected to get launched during the study period. The analysis covers the Intermittent Claudication market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Intermittent Claudication Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Intermittent Claudication Market Will Evolve by 2032 @

Some of the key companies in the Intermittent Claudication therapeutics market include:

  • Pluristem

  • Venturis Therapeutics, Inc.

And many more

Intermittent Claudication Therapies covered in the report include:


  • FGF-1

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Intermittent Claudication Competitive Intelligence Analysis

4. Intermittent Claudication Market Overview at a Glance

5. Intermittent Claudication Disease Background and Overview

6. Intermittent Claudication Patient Journey

7. Intermittent Claudication Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Intermittent Claudication Treatment Algorithm, Current Treatment, and Medical Practices

9. Intermittent Claudication Unmet Needs

10. Key Endpoints of Intermittent Claudication Treatment

11. Intermittent Claudication Marketed Products

12. Intermittent Claudication Emerging Drugs and Latest Therapeutic Advances

13. Intermittent Claudication Seven Major Market Analysis

14. Attribute Analysis

15. Intermittent Claudication Market Outlook (In US, EU5, and Japan)

16. Intermittent Claudication Access and Reimbursement Overview

17. KOL Views on the Intermittent Claudication Market

18. Intermittent Claudication Market Drivers

19. Intermittent Claudication Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Intermittent Claudication Pipeline Insight

DelveInsight’s “Intermittent Claudication Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Intermittent Claudication market. The report embraces in-depth commercial and clinical assessment of the Intermittent Claudication pipeline products from the pre-clinical developmental phase to the marketed phase, along with the key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States